Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease
Research in the last decades has demonstrated the relevance of epigenetics in controlling gene expression to maintain cell homeostasis, and the important role played by epigenome alterations in disease development. Moreover, the reversibility of epigenetic marks can be harnessed as a therapeutic str...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/6/1265 |
| _version_ | 1797541569907130368 |
|---|---|
| author | María Arechederra Miriam Recalde María Gárate-Rascón Maite G. Fernández-Barrena Matías A. Ávila Carmen Berasain |
| author_facet | María Arechederra Miriam Recalde María Gárate-Rascón Maite G. Fernández-Barrena Matías A. Ávila Carmen Berasain |
| author_sort | María Arechederra |
| collection | DOAJ |
| description | Research in the last decades has demonstrated the relevance of epigenetics in controlling gene expression to maintain cell homeostasis, and the important role played by epigenome alterations in disease development. Moreover, the reversibility of epigenetic marks can be harnessed as a therapeutic strategy, and epigenetic marks can be used as diagnosis biomarkers. Epigenetic alterations in DNA methylation, histone post-translational modifications (PTMs), and non-coding RNA (ncRNA) expression have been associated with the process of hepatocarcinogenesis. Here, we summarize epigenetic alterations involved in the pathogenesis of chronic liver disease (CLD), particularly focusing on DNA methylation. We also discuss their utility as epigenetic biomarkers in liquid biopsy for the diagnosis and prognosis of hepatocellular carcinoma (HCC). Finally, we discuss the potential of epigenetic therapeutic strategies for HCC treatment. |
| first_indexed | 2024-03-10T13:17:49Z |
| format | Article |
| id | doaj.art-d97c6f223693485e8547073dc7da0e8b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T13:17:49Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d97c6f223693485e8547073dc7da0e8b2023-11-21T10:17:14ZengMDPI AGCancers2072-66942021-03-01136126510.3390/cancers13061265Epigenetic Biomarkers for the Diagnosis and Treatment of Liver DiseaseMaría Arechederra0Miriam Recalde1María Gárate-Rascón2Maite G. Fernández-Barrena3Matías A. Ávila4Carmen Berasain5Program of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, SpainProgram of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, SpainProgram of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, SpainProgram of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, SpainProgram of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, SpainProgram of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, SpainResearch in the last decades has demonstrated the relevance of epigenetics in controlling gene expression to maintain cell homeostasis, and the important role played by epigenome alterations in disease development. Moreover, the reversibility of epigenetic marks can be harnessed as a therapeutic strategy, and epigenetic marks can be used as diagnosis biomarkers. Epigenetic alterations in DNA methylation, histone post-translational modifications (PTMs), and non-coding RNA (ncRNA) expression have been associated with the process of hepatocarcinogenesis. Here, we summarize epigenetic alterations involved in the pathogenesis of chronic liver disease (CLD), particularly focusing on DNA methylation. We also discuss their utility as epigenetic biomarkers in liquid biopsy for the diagnosis and prognosis of hepatocellular carcinoma (HCC). Finally, we discuss the potential of epigenetic therapeutic strategies for HCC treatment.https://www.mdpi.com/2072-6694/13/6/1265precision medicineDNA methylationepidrugsliquid biopsyhepatocellular carcinomaliver fibrosis |
| spellingShingle | María Arechederra Miriam Recalde María Gárate-Rascón Maite G. Fernández-Barrena Matías A. Ávila Carmen Berasain Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease Cancers precision medicine DNA methylation epidrugs liquid biopsy hepatocellular carcinoma liver fibrosis |
| title | Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease |
| title_full | Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease |
| title_fullStr | Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease |
| title_full_unstemmed | Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease |
| title_short | Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease |
| title_sort | epigenetic biomarkers for the diagnosis and treatment of liver disease |
| topic | precision medicine DNA methylation epidrugs liquid biopsy hepatocellular carcinoma liver fibrosis |
| url | https://www.mdpi.com/2072-6694/13/6/1265 |
| work_keys_str_mv | AT mariaarechederra epigeneticbiomarkersforthediagnosisandtreatmentofliverdisease AT miriamrecalde epigeneticbiomarkersforthediagnosisandtreatmentofliverdisease AT mariagaraterascon epigeneticbiomarkersforthediagnosisandtreatmentofliverdisease AT maitegfernandezbarrena epigeneticbiomarkersforthediagnosisandtreatmentofliverdisease AT matiasaavila epigeneticbiomarkersforthediagnosisandtreatmentofliverdisease AT carmenberasain epigeneticbiomarkersforthediagnosisandtreatmentofliverdisease |